The completion of Phase I of manufacturing upgrades by Cana Laboratories, a subsidiary of Cosmos Health, is a significant milestone. This development is expected to enhance the company's profitability, with projections of over $10 million in recurring annual gross profit by the end of 2025. This positive financial outlook is likely to boost investor confidence and positively impact COSM's stock price in the short term.